Shandong Sinobioway Biomedicine Co., Ltd. Stocks

CN¥ 6.75Last Updated 30.04.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 686.11M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 6.75
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Sinobioway Biomedicine Co., Ltd. manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, nerve growth factor, and alfaron in China. The company also provides NOBEX, a murine nerve growth factor for injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b spray. In addition, it offers Healive, an inactivated hepatitis A vaccine; Bilive, a combined hepatitis A and B Vaccine; Panflu, a pandemic influenza vaccine; Anflu, a preservative-free influenza virus vaccine; Panflu.1, a Type A H1N1 influenza vaccine; etc. Further, the company exports its products to approximately 20 counties and regions in Europe and the United States. Shandong Sinobioway Biomedicine Co., Ltd. was founded in 2000 and is headquartered in Zibo, China.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks